Maziar “Mike” Doustdar is the chief executive of Novo Nordisk. In that role, he’s driving its global operations at a particularly difficult time when the company suddenly finds itself at the center of a health and economic transformation. As the leader overseeing international markets, manufacturing, and supply strategy, he’s the person ensuring the world can access Wegovy and Ozempic, the blockbuster GLP-1 drugs reshaping obesity and diabetes care.
His influence is huge because demand for these medicines is exploding, and supply is the industry’s biggest bottleneck. Doustdar is the one orchestrating massive factory expansions, new production partnerships, and global distribution plans that determine who gets these drugs, when, and at what scale. Governments, insurers, and health systems are all watching his moves.
With GLP-1s affecting everything from public health to food companies and national budgets, the executive controlling Novo Nordisk’s global engine naturally becomes a major power player.
